

Serial No. : 08/210,902  
Filed : March 21, 1994

*Q1*  
*Q11*  
*Qent*  
introducing a polynucleotide to said blood vessel after said mechanical treatment, said polynucleotide comprising a thymidine kinase gene;

expressing said thymidine kinase gene to produce thymidine kinase protein in cells of said blood vessel; and

then administering to said mammal an effective amount of a DNA replication-inhibiting nucleoside analog capable of being phosphorylated by said thymidine kinase protein [and], whereby said phosphorylated analog is preferentially [incorporating] incorporated [said phosphorylated analog] into the DNA of proliferating cells, and whereby said proliferating cells are killed.

Claim 4, line 2, following "vector is", please delete "in".

*Q2*  
*11.6* (Amended) The method of Claim ~~10~~ <sup>11.6</sup>, further comprising an adenoviral vector enhancer [elements] element, encapsidation [signals] signal and [origins] origin of replication [and other necessary adenoviral genes].

*Q3*  
*12.1* (Amended) The method of Claim 1, wherein said [suicide compound] nucleoside analog is ganciclovir or acyclovir.

*Q4*  
*13* (Amended) The method of Claim [13] 1, wherein said phosphorylated [compound] analog is further phosphorylated by intracellular enzymes.

#### REMARKS

Claims 13 and 16-20 have been canceled without prejudice.  
Claims 1, 4, 7, 12 and 14 have been amended. Thus, Claims 1-12, 14